Loading organizations...
§ Private Profile · 150 Baker Avenue Ext Ste 300, MA, USA
Telcare is a technology company.
Telcare develops a comprehensive digital health solution, featuring the world's first cellular-enabled blood glucometer. This system integrates a diabetes mobile application and HIPAA-compliant cloud platform, enabling wireless data transmission and messaging. It provides real-time monitoring and remote management, fostering direct connection between patients and healthcare professionals.
Founded in 2008 by Dr. Javitt, the company's insight addressed the critical need to modernize diabetes care. He recognized the limitations of manual blood glucose tracking and mobile technology's potential to bridge communication gaps. Dr. Javitt envisioned empowering individuals with diabetes and offering clinicians immediate patient health insights.
Telcare’s products serve individuals managing diabetes and their supporting healthcare providers. The platform aims to improve patient adherence and health outcomes through accessible, continuous monitoring and personalized feedback. Its vision is to advance chronic disease management via connected care, easing the burden of living with long-term conditions.
Telcare has raised $58.5M across 2 funding rounds.
Telcare has raised $58.5M in total across 2 funding rounds.
Telcare has raised $58.5M in total across 2 funding rounds.
Telcare's investors include Casper de Clercq, Canaan Partners, Norwest Venture Partners, Mosaic Health Solutions, Qualcomm, Sequoia Capital, Scott Carter, Jack Young.
Telcare has raised $58.5M across 2 funding rounds. Most recently, it raised $33.0M Series C in October 2014.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 1, 2014 | $33M Series C | Casper DE Clercq | Canaan Partners, Norwest Venture Partners, Mosaic Health Solutions, Qualcomm, Sequoia Capital | Announced |
| Aug 22, 2012 | $25.5M Series B | Scott Carter | Jack Young | Announced |
Telcare is a digital health company specializing in diabetes management through connected glucose monitoring devices and cloud-based analytics. It developed the world's first FDA-cleared cellular-enabled blood glucose meter in 2011, which transmits readings instantly to caregivers via wireless M2M technology, enabling real-time feedback, coaching, and an ecosystem involving patients, family, and clinicians.[1][3] Serving the $12 billion global glucose monitoring market—particularly the 28 million Americans with diabetes—Telcare's solution includes the meter, FDA-cleared cloud server, and smartphone apps for data sharing, addressing poor adherence to testing and remote monitoring gaps.[1] Acquired by BioTelemetry in December 2016 and operating as its division, Telcare collaborated with Onduo (Verily-Sanofi JV) in 2017 to supply devices for Type 2 diabetes programs, demonstrating growth through partnerships.[3]
Telcare emerged around 2008, initially based in Concord, Massachusetts (with a later reference to Potsdam, Germany), founded to bridge the "last mile" between patients and caregivers using wireless technology for chronic disease management.[1][4] The core idea crystallized with its flagship product: the first cellular glucose meter, FDA-cleared in 2011, which automated data transmission to servers for instant coaching—sparking early buzz in outlets like the Wall Street Journal and Forbes.[1] Pivotal traction came from awards, including CTIA E-Tech first places for mobile and enterprise health solutions, Frost & Sullivan's best patient monitoring prize, and a Triple Tree iAward finalist nod.[1] By 2016, BioTelemetry acquired it to bolster its wireless medical tech portfolio, shifting focus to integrated diabetes suites with cloud analytics and care tools.[3]
Telcare rides the mHealth and remote patient monitoring wave, capitalizing on rising diabetes prevalence (e.g., 28 million U.S. cases) and the shift to connected devices amid a $12B glucometer market.[1] Timing aligned with FDA clearances for wireless health post-2011 and acquisitions by firms like BioTelemetry, fueling digital health consolidation.[3] Market forces like smartphone penetration, cloud analytics demand, and payer incentives for outcomes-based care favor its model, influencing ecosystems by enabling data-driven interventions—paving the way for AI-enhanced coaching and JV integrations like Onduo.[1][3] It exemplifies how medtech startups amplify impact via big-tech partnerships, standardizing real-time chronic care.
Telcare's trajectory points to deeper AI-driven personalization in diabetes tech, potentially expanding beyond glucose to multi-vital platforms amid post-2017 partnerships. Trends like value-based care and wearables will propel demand for its instant-data edge, evolving its role from device maker to ecosystem enabler—possibly via BioTelemetry spin-offs or further Alphabet/Sanofi ties. As connected health matures, Telcare remains poised to redefine patient empowerment, echoing its 2011 breakthrough in a more integrated future.